Cholangiocarcinoma News

Survival Outcomes in Patients with iCCA and Solitary versus Multiple Tumors

March 2023, Vol 4, No 1

Previously, the staging system developed by the American Joint Committee on Cancer (AJCC) for intrahepatic cholangiocarcinoma (iCCA) separated a solitary tumor without vascular invasion and multiple tumors with or without vascular invasion into different categories, T2a and T2b. The latest staging system by AJCC groups a solitary tumor with vascular invasion and multiple tumors together as T2. Many recent studies, however, have suggested that patients with multifocal iCCA have a worse prognosis compared with those with a single lesion. Dr So Jeong Yoon reported results from a retrospective study aimed at investigating the risk factors for iCCA and the prognostic significance of tumor multiplicity identified by surgical resection.

Between 2010 and 2019, 257 patients underwent surgery for iCCA and had clinicopathological data available for review. Risk factor analysis identified variables associated with survival of patients with resected iCCA, and survival outcomes were compared between patients with solitary versus multiple tumors. Identified risk factors for survival included preoperative symptoms, tumor size, lymph node ratio, multiplicity, and tumor differentiation.

A total of 82 patients were classified as T2, and among these patients, overall survival (OS) was significantly better in patients with solitary tumors (sT2) compared with those with multiple tumors (mT2; P = .017). Survival was compared among patients with stage II sT2 (II-sT2), stage II mT2 (II-mT2), and stage III disease. OS was 52 months in II-sT2 patients versus 29 months in II-mT2 patients (P = .010), and OS was 15 months in patients with IIIA disease (P = .012 vs II-sT2). OS was not statistically different between patients with II-mT2 disease versus those with stage IIIA or IIIB disease: 29 months versus 15 months and 23 months, respectively.

Results from this study highlight a need for multiplicity to be reflected in the AJCC staging system and suggest this difference should be reflected in the next update of the staging guidelines.

Source: Yoon SJ, Oh S, Jeon HJ, et al. The oncologic implications of tumor multiplicity in intrahepatic cholangiocarcinoma: its prognostic value might be underestimated. Poster presented at: ASCO Gastrointestinal Cancers Symposium, January 19-21, 2023; San Francisco, CA. Abstract 611.

Related Items

Characterization of Long-Term Survivors in TOPAZ-1
March 2023, Vol 4, No 1
Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.
MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC
March 2023, Vol 4, No 1
The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.
Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study
March 2023, Vol 4, No 1
Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.
Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC
March 2023, Vol 4, No 1
CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.
Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements
March 2023, Vol 4, No 1
Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.
Results from SWOG 1815: GemCis and Nab-Paclitaxel versus GemCis in Advanced BTC
March 2023, Vol 4, No 1
The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.
JCOG1202 Subgroup Analysis: Risk Factors for Early Relapse in Patients Undergoing Curative Resection
March 2023, Vol 4, No 1
A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.
Impact of Gene Expression in 5-FU Metabolic Pathways on Outcomes in Patients Enrolled in JCOG1202
March 2023, Vol 4, No 1
Results from a study evaluating the impact of 5-FU metabolic pathway enzyme expression on outcomes of patients with curatively resected biliary tract cancer showed that relapse-free survival was improved in patients with certain enzymes who received adjuvant S-1.
Atezolizumab with or without Bevacizumab in Combination with GemCis in Advanced BTC: Results from IMbrave 151
March 2023, Vol 4, No 1
Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.
Nab-Paclitaxel plus Sintilimab as Second-Line Treatment for Advanced BTC
March 2023, Vol 4, No 1
The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: